公开(公告)号：EP0722439A1

公开(公告)日：1996-07-24

申请号：EP94930609.0

申请日：1994-10-07

申请人： AGOURON PHARMACEUTICALS, INC.

发明人： DRESSMAN, Bruce, A. ,  FRITZ, James, E. ,  HAMMOND, Marlys ,  HORNBACK, William, J. ,  KALDOR, Stephen, W. ,  KALISH, Vincent, J. ,  MUNROE, John, E. ,  REICH, Siegfried, Heinz ,  TATLOCK, John, H. ,  SHEPHERD, Timothy, A. ,  RODRIGUEZ, Michael, J. ,  JUNGHEIM, Louis, N.

IPC分类号： C07D295 ,  A61K31 ,  A61P31 ,  A61P43 ,  C07C237 ,  C07C323 ,  C07D207 ,  C07D209 ,  C07D211 ,  C07D213 ,  C07D215 ,  C07D217 ,  C07D233 ,  C07D401 ,  C07D403 ,  C07D409 ,  C07D417 ,  C07D471 ,  C07D495 ,  C07F9 ,  C07K5

CPC分类号： C07D401/06 ,  C07C237/42 ,  C07C323/60 ,  C07D207/16 ,  C07D209/08 ,  C07D211/60 ,  C07D213/40 ,  C07D215/48 ,  C07D215/50 ,  C07D217/02 ,  C07D217/06 ,  C07D217/26 ,  C07D401/12 ,  C07D403/14 ,  C07D409/12 ,  C07D417/12 ,  C07D495/04 ,  C07F9/62

摘要： HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

公开(公告)号：EP0722439B1

公开(公告)日：2002-08-14

申请号：EP94930609.6

申请日：1994-10-07

申请人： AGOURON PHARMACEUTICALS, INC.

发明人： DRESSMAN, Bruce, A. ,  FRITZ, James, E. ,  HAMMOND, Marlys ,  HORNBACK, William, J. ,  KALDOR, Stephen, W. ,  KALISH, Vincent, J. ,  MUNROE, John, E. ,  REICH, Siegfried, Heinz ,  TATLOCK, John, H. ,  SHEPHERD, Timothy, A. ,  RODRIGUEZ, Michael, J. ,  JUNGHEIM, Louis, N.

IPC分类号： C07D217/26 ,  C07D495/04 ,  C07F9/62 ,  C07D401/06

CPC分类号： C07D401/06 ,  C07C237/42 ,  C07C323/60 ,  C07D207/16 ,  C07D209/08 ,  C07D211/60 ,  C07D213/40 ,  C07D215/48 ,  C07D215/50 ,  C07D217/02 ,  C07D217/06 ,  C07D217/26 ,  C07D401/12 ,  C07D403/14 ,  C07D409/12 ,  C07D417/12 ,  C07D495/04 ,  C07F9/62

摘要： HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.